Gefitinib Matsakaici CAS 199327-61-2 Tsarkake>99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. shine babban kamfani na 7-Methoxy-6- (3-Morpholin-4-ylpropoxy) quinazolin-4 (3H) - Daya (CAS: 199327-61-2) tare da babban inganci, matsakaici. na Gefitinib (CAS: 184475-35-2).Ruifu Chemical na iya samar da isar da saƙo na duniya, farashi mai gasa, kyakkyawan sabis, ƙanana da adadi mai yawa akwai.Sayi Gefitinib Intermediates,Please contact: alvin@ruifuchem.com
| Sunan Sinadari | 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H) -Daya |
| Makamantu | 7-Methoxy-6- (3-Morpholinopropoxy) quinazolin-4 (3H) - Daya;7-Methoxy-6-[3- (4-Morpholinyl) wakili] -4 (3H) -Quinazolinone;7-Methoxy-6-(3-Morpholinopropoxy) quinazolin-4-Daya |
| kazanta | Gefitinib rashin tsarki 5;Gefitinib EP Impurity A |
| Matsayin Hannun jari | A Stock, Kasuwancin Kasuwanci |
| Lambar CAS | 199327-61-2 |
| Tsarin kwayoyin halitta | Saukewa: C16H21N3O4 |
| Nauyin Kwayoyin Halitta | 319.36 g/mol |
| Matsayin narkewa | 242.0 ~ 247.0 ℃ |
| Yawan yawa | 1.32± 0.10 g/cm3 |
| COA & MSDS | Akwai |
| Asalin | Shanghai, China |
| Alamar | Ruifu Chemical |
| Abubuwa | Ka'idojin dubawa | Sakamako |
| Bayyanar | Fari zuwa Kashe-Farin Foda | Ya bi |
| Matsayin narkewa | 242.0 ~ 247.0 ℃ | 243.6 ~ 244.5 ℃ |
| Asara akan bushewa | <0.50% | 0.15% |
| Ragowa akan Ignition | <0.20% | 0.11% |
| Tsaftace Guda Daya | <0.50% | <0.30% |
| Jimlar ƙazanta | <1.00% | 0.30% |
| Tsarkake / Hanyar Bincike | > 99.0% (HPLC) | 99.7% |
| 1H NMR Spectrum | Daidai da Tsarin | Ya bi |
| Kammalawa | An gwada samfurin kuma ya dace da ƙayyadaddun da aka bayar | |
| Aikace-aikace | Matsakaicin Gefitinib (CAS: 184475-35-2) | |
Kunshin:Fluorinated Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye akwati sosai kuma a adana a wuri mai sanyi, bushe (2 ~ 8 ℃) da ma'ajin da ke da isasshen iska daga abubuwan da ba su dace ba.Kare daga haske da danshi.
Jirgin ruwa:Isar da shi zuwa duniya ta iska, ta FedEx / DHL Express.Bayar da isarwa cikin sauri kuma abin dogaro.
Yadda ake siya?Da fatan za a tuntuɓiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Kwarewar Shekaru 15?Muna da fiye da shekaru 15 na gwaninta a cikin ƙira da fitarwa na matsakaicin matsakaicin magunguna masu inganci ko sinadarai masu kyau.
Manyan Kasuwanni?Sayarwa zuwa kasuwannin cikin gida, Arewacin Amurka, Turai, Indiya, Koriya, Jafananci, Australia, da sauransu.
Fa'idodi?Babban inganci, farashi mai araha, sabis na ƙwararru da tallafin fasaha, bayarwa da sauri.
inganciTabbaci?Tsananin kula da ingancin inganci.Kayan aikin ƙwararru don bincike sun haɗa da NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, gwajin ƙayyadaddun ƙwayoyin cuta, da sauransu.
Misali?Yawancin samfurori suna ba da samfurori kyauta don ƙima mai kyau, farashin jigilar kaya ya kamata a biya ta abokan ciniki.
Binciken Masana'antu?Ma'aikata duba maraba.Da fatan za a yi alƙawari a gaba.
MOQ?Babu MOQ.Karamin tsari abin karɓa ne.
Lokacin Bayarwa? Idan cikin hannun jari, garantin isar da kwana uku.
Sufuri?By Express (FedEx, DHL), ta Air, ta Teku.
Takardu?Bayan sabis na tallace-tallace: COA, MOA, ROS, MSDS, da dai sauransu za a iya ba da su.
Tsarin al'ada?Zai iya ba da sabis na haɗawa na al'ada don dacewa da buƙatun bincikenku.
Sharuɗɗan Biyan kuɗi?Za a fara aiko da daftari na Proforma bayan tabbatar da oda, an rufe bayanan bankin mu.Biya ta T/T (Telex Transfer), PayPal, Western Union, da dai sauransu.
7-Methoxy-6- (3-Morpholin-4-ylpropoxy) quinazolin-4 (3H) -Daya (CAS: 199327-61-2) shine matsakaici / ƙazanta na Gefitinib (CAS: 184475-35-2).Gefitinib wani takamaiman maganin cutar kansa ne wanda aka yi niyya na warkewa wanda AstraZeneca, UK ya haɓaka.Gefitinib shine magani na farko da aka yi niyya na ƙwayoyin cuta don maganin kansar huhu mara ƙarami.Yana aiki ta hanyar zaɓin hana hanyar watsa sigina na mai karɓar haɓakar haɓakar haɓakar epidermal tyrosine kinase (EGFR-TK).A watan Agustan 2002, Gefitinib ya fara kasuwa a Japan a matsayin magani na farko don ciwon daji na huhu mara karami a karkashin sunan kasuwanci Iressa.A cikin Mayu 2003, Hukumar Abinci da Magunguna ta Amurka ta amince da Gefitinib a matsayin na uku-monotherapy ga marasa lafiya tare da ci-gaba marasa kanana huhu ciwon daji wadanda ba su da tasiri tare da platinum na tushen anticancer kwayoyi da docetaxel chemotherapy.A halin yanzu, Ostiraliya, Japan, Argentina, Singapore da Koriya ta Kudu sun amince da Gefitinib don maganin ciwon daji na huhu wanda ba ƙananan ƙwayoyin cuta ba.A ranar 28 ga Fabrairu, 2005, Hukumar Kula da Abinci da Magunguna ta kasar Sin ta amince da Gefitinib don kula da ciwon daji na huhu na cikin gida ko na metastatic (NSCLC) wanda a baya ya sami ilimin chemotherapy.A halin yanzu ba a yarda da shi don amfani azaman jigon layin farko don ci gaba na NSCLC ba.A ranar 1 ga Yuli, 2009, Hukumar Kula da Magunguna ta Turai ta amince da Gefitinib bisa hukuma don layin farko, layi na biyu da jiyya na layi na uku na ci gaba a cikin gida ko metastatic marasa ƙananan ƙwayoyin huhu tare da maye gurbin EGFR a cikin manya.
